⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
ACAD News
Acadia Pharmaceuticals Inc.
Form 8-K
sec.gov
ACAD
European Commission Approves DAYBU ® (trofinetide) as the First and Only Treatment for Neurobehavioral Symptoms of Rett Syndrome in the European Union
businesswire.com
ACAD
ADARx Pharmaceuticals Expands Leadership Team with Board and Executive Appointments
globenewswire.com
ACAD
LGND
Global Neurodegenerative Disease Market is Expected to Showcase Significant Growth at a CAGR of ~6% by 2034 | DelveInsight
globenewswire.com
NVO
LLY
BMY
AXSM
JNJ
SNY
BIIB
ABBV
MRK
REGN
GILD
AMGN
AZN
TEVA
BHC
ALKS
VRTX
SRPT
CRIS
NTLA
EDIT
INCY
ACAD
ALNY
CYTK
IONS
EXAS
IDXX
VNDA
SUPN
RGNX
XOM
CVAC
BNTX
ARCT
MRNA
NBIX
ADPT
AVXL
IMUX
PRGS
RDNT
CRDF
ADSK
ANAB
ATRC
CLDX
CPRX
ESPR
EXEL
FGEN
GALT
GRFS
HRMY
IGC
INSM
KODK
LAKE
LCTX
LEXX
LPCN
MESO
MITK
MNKD
MSFT
MYGN
NEO
NVCR
NXPI
OCGN
OMER
ORCL
PACB
PFE
PLRX
PRGO
PSNL
PTGX
QGEN
RARE
ROST
RVMD
SEIC
SIGA
SMCI
SNOW
SOFI
SPRO
TGTX
TNDM
TXG
ULTA
VEEV
VKTX
VRNS
WVE
XRAY
ZBRA
ZNTL
Form 8-K
sec.gov
ACAD
Dementia-related Psychosis Market Gearing Up for Outstanding Expansion at a CAGR of 26.2% During the Forecast Period (2026-2036) | DelveInsight
prnewswire.com
ACAD
BMY
JNJ
Acadia Pharmaceuticals to Participate in the Canaccord Genuity 46th Annual Growth Conference
businesswire.com
ACAD
American College of Surgeons and Arcadia Collaborate to Improve Surgical Patient Outcomes
prnewswire.com
ACAD
Parkinson's Disease Clinical Trial Pipeline Boom as 150+ Companies are in the Race for Better Treatments | DelveInsight
globenewswire.com
ANVS
SUPN
ABBV
VNDA
JAZZ
ACAD
MRK
Acadia Pharmaceuticals to Announce Second Quarter 2026 Financial Results on August 4, 2026
businesswire.com
ACAD